Eikon Therapeutics (NASDAQ:EIKN – Get Free Report) had its target price lowered by analysts at Morgan Stanley to $30.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Morgan Stanley‘s price objective points to a potential upside of 479.15% from the company’s current price.
Several other analysts also recently commented on the stock. Wall Street Zen upgraded shares of Eikon Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Mizuho upgraded shares of Eikon Therapeutics to a “strong-buy” rating in a report on Wednesday, September 16th. Weiss Ratings upgraded shares of Eikon Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday. HC Wainwright initiated coverage on shares of Eikon Therapeutics in a research note on Friday, October 16th. They issued a “buy” rating and a $23.00 price objective for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Eikon Therapeutics in a research note on Friday, August 21st. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $24.33.
Get Our Latest Research Report on Eikon Therapeutics
Eikon Therapeutics Stock Up 0.6%
Eikon Therapeutics (NASDAQ:EIKN – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($1.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.74) by $0.15. On average, research analysts expect that Eikon Therapeutics will post -7.04 EPS for the current year.
Insider Transactions at Eikon Therapeutics
In other Eikon Therapeutics news, major shareholder Group Iv Gp Lp Column bought 89,200 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The stock was purchased at an average cost of $11.56 per share, with a total value of $1,031,152.00. Following the transaction, the insider directly owned 89,200 shares in the company, valued at $1,031,152. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Hedge Funds Weigh In On Eikon Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. increased its stake in shares of Eikon Therapeutics by 29.0% during the 2nd quarter. BlackRock Inc. now owns 4,281,425 shares of the company’s stock worth $55,873,000 after purchasing an additional 962,046 shares during the last quarter. Regents of The University of California purchased a new position in Eikon Therapeutics in the third quarter valued at approximately $5,106,000. State Street Corp lifted its stake in Eikon Therapeutics by 71.9% in the third quarter. State Street Corp now owns 608,838 shares of the company’s stock valued at $4,895,000 after purchasing an additional 254,745 shares during the last quarter. StepStone Group LP grew its holdings in Eikon Therapeutics by 32.4% during the third quarter. StepStone Group LP now owns 523,467 shares of the company’s stock valued at $4,209,000 after purchasing an additional 128,127 shares during the period. Finally, Parkman Healthcare Partners LLC bought a new position in Eikon Therapeutics during the second quarter valued at $3,341,000.
About Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company focused on discovering and developing medicines for serious diseases, including cancer. The company uses advanced imaging, computational biology and drug-discovery methods to study how proteins behave in living cells and identify potential therapeutic targets. Founded in 2019 by Roger Perlmutter, a former head of Merck Research Laboratories, Eikon is based in California. Its work is centered on research and development; the company is not known for marketed medicines.
See Also
- Five stocks we like better than Eikon Therapeutics
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
Receive News & Ratings for Eikon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eikon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
